Mayra is testing which B2B lane to build in — the market will name itself here soon.
Public enforcement, labor-market, and industry data across the lanes I’m testing — updated as it publishes.
- →FDA warning letter issued to a Philadelphia pharma manufacturer for unresolved CGMP lab findings, April 2026
- →PayPal cut 4,760 roles (~20% of staff) in a restructuring targeting $1.5B in run-rate savings, May 2026
- →ASA Staffing Index up 4.8% year-over-year, new-assignment starts rising 6.9% week-over-week, May 2026
- →Omnicom folded DDB and MullenLowe into TBWA after 4,000+ cuts following its $13B Interpublic acquisition, December 2025
Sourced from FDA warning letters, ASA staffing index reports, and ad-industry restructuring coverage (Adweek, AdAge).
No deal to point at yet — so here’s where things stand.
Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.